| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/24/2010 | EP2252618A1 PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS |
| 11/24/2010 | EP2252617A1 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| 11/24/2010 | EP2252616A1 Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
| 11/24/2010 | EP2252615A1 Dihydro- 1h- pyrrolo [1,2-a]indol-1-yl carboxylic derivatives which act as s1p1 agonists |
| 11/24/2010 | EP2252614A1 Novel 3,8-diaza-bicyclo[3.2.1]octane- and 3,9-diaza-bicyclo[3.3.1]-nonane-3-carboxylic acid ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 11/24/2010 | EP2252613A1 Compounds and compositions as modulators of gpr119 activity |
| 11/24/2010 | EP2252612A1 Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| 11/24/2010 | EP2252611A1 (dihydro)pyrrolo[2,1-a]isoquinolines |
| 11/24/2010 | EP2252610A1 Substituted piperidines as renin inhibitors |
| 11/24/2010 | EP2252609A1 Pyridin-2-yl derivatives as immunomodulating agents |
| 11/24/2010 | EP2252608A1 Method for treating pain syndrome and other disorders |
| 11/24/2010 | EP2252607A2 Novel polymorphs and processes for their preparation |
| 11/24/2010 | EP2252605A2 Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
| 11/24/2010 | EP2252604A1 Thiazole derivative and use thereof as vap-1 inhibitor |
| 11/24/2010 | EP2252603A1 The hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor |
| 11/24/2010 | EP2252601A1 Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 11/24/2010 | EP2252599A1 Triazole amide derivatives for use in therapy |
| 11/24/2010 | EP2252598A2 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 11/24/2010 | EP2252597A2 Novel compounds, use and preparation thereof |
| 11/24/2010 | EP2252596A1 Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings |
| 11/24/2010 | EP2252595A1 Oxim derivatives as hsp90 inhibitors |
| 11/24/2010 | EP2252593A1 Substituted pyridazine derivatives which have histamine h3 antagonist activity |
| 11/24/2010 | EP2252592A1 Arylchalcogeno-arylalkyl-substituted imidazolidine-2,4-diones, method for the production thereof, medicaments containing said compounds and use thereof |
| 11/24/2010 | EP2252591A1 Aryl-substituted imidazolidine-2,4-diones, method for the production thereof, medicaments containing said compounds and use thereof |
| 11/24/2010 | EP2252589A2 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| 11/24/2010 | EP2252587A1 Piperidine sulfonamide derivatives |
| 11/24/2010 | EP2252586A1 Compounds and compositions as modulators of gpr119 activity |
| 11/24/2010 | EP2252585A1 Methods of preparing polymorphic form a of bazedoxifene acetate |
| 11/24/2010 | EP2252583A1 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity |
| 11/24/2010 | EP2252581A1 Kappa selective opioid receptor antagonist |
| 11/24/2010 | EP2252578A1 Novel conjugates for treating neurodegenerative diseases and disorders |
| 11/24/2010 | EP2252575A1 2-amino-2-phenylalkanol derivatives, preparation thereof and pharmaceutical compositions containing same |
| 11/24/2010 | EP2252573A2 New polymorph and amorphous forms of desvenlafaxine fumarate |
| 11/24/2010 | EP2252569A2 Antiinfective and antitumoral compounds isolated from tropical lianas |
| 11/24/2010 | EP2252372A1 2-aminoquinolines |
| 11/24/2010 | EP2252327A2 Methods of treating copd |
| 11/24/2010 | EP2252326A1 Vaccine compositions |
| 11/24/2010 | EP2252323A2 Genetic regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species |
| 11/24/2010 | EP2252321A2 Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor |
| 11/24/2010 | EP2252318A2 Methods of treating inflammation |
| 11/24/2010 | EP2252317A2 A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration |
| 11/24/2010 | EP2252311A1 Heteroaryl-containing tripeptide hcv serine protease inhibitors |
| 11/24/2010 | EP2252309A1 Nutritional compositions for promotion of bone growth and maintenance of bone health comprising extracts of for example rosemary or caraway |
| 11/24/2010 | EP2252306A1 Novel use of probiotics |
| 11/24/2010 | EP2252304A2 Platinum aggregates and process for producing the same |
| 11/24/2010 | EP2252303A2 Von willebrand factor specific binders and methods of use therefor |
| 11/24/2010 | EP2252302A1 Composition for the treatment of osteoarthritis |
| 11/24/2010 | EP2252301A1 Use of ulipristal for treating uterine fibroids |
| 11/24/2010 | EP2252300A1 Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis |
| 11/24/2010 | EP2252299A1 Fused pyridone m1 receptor positive allosteric modulators |
| 11/24/2010 | EP2252298A1 Compositions and methods for treating lung cancer |
| 11/24/2010 | EP2252297A1 Protective effect of high dose folate on mycardial ischemia |
| 11/24/2010 | EP2252296A1 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 11/24/2010 | EP2252295A1 Use of ranolazine for the treatment of cardiovascular diseases |
| 11/24/2010 | EP2252294A1 Use of ranolazine for treating pain |
| 11/24/2010 | EP2252293A2 Kinase inhibitors and methods of use |
| 11/24/2010 | EP2252292A2 Cardioplegia solution for cardiac surgery |
| 11/24/2010 | EP2252291A1 Pharmaceutical composition |
| 11/24/2010 | EP2252290A1 Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases |
| 11/24/2010 | EP2252289A1 Combination therapy comprising sglt inhibitors and dpp4 inhibitors |
| 11/24/2010 | EP2252288A1 Treatment of protein folding disorders |
| 11/24/2010 | EP2252287A1 Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics |
| 11/24/2010 | EP2252286A2 Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria |
| 11/24/2010 | EP2252285A1 Abnormal intraocular pressure treatment |
| 11/24/2010 | EP2252284A1 Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| 11/24/2010 | EP2252283A1 Synthetic triterpenoids and methods of use in the treatment of disease |
| 11/24/2010 | EP2252282A2 Cosmetic and/or dermatological composition |
| 11/24/2010 | EP2252281A2 Blood substitute solution |
| 11/24/2010 | EP2252280A1 Use of eicosapentaenoic acid and/or docosahexahenoic acid in women with endometriosis |
| 11/24/2010 | EP2252279A1 Amino acid formulations comprising cysteine, methionine and/or serine for the prevention of paracetamol-induced liver damage |
| 11/24/2010 | EP2252278A2 Compounds for use in the treatment of neuropathic pain |
| 11/24/2010 | EP2252277A2 Acetyl mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase |
| 11/24/2010 | EP2252276A1 Methods for the treatment and prevention of age-related retinal dysfunction |
| 11/24/2010 | EP2252275A2 Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| 11/24/2010 | EP2252273A1 Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic |
| 11/24/2010 | EP2252270A2 Formulations of flibanserin |
| 11/24/2010 | EP2252269A1 Casein particles encapsulating therapeutically active agents and uses thereof |
| 11/24/2010 | EP2252268A1 Pulmonary formulations of triptans |
| 11/24/2010 | EP2252265A2 Injectable preparations and a process of preparation thereof |
| 11/24/2010 | EP2252263A1 Galenic form for the oral transmucosal delivery of triptans |
| 11/24/2010 | EP2252262A1 Method to enhance aqueous solubility of poorly soluble actives using methoxypolyethylene glycol |
| 11/24/2010 | EP2252261A2 Drug delivery system with stabilising effect |
| 11/24/2010 | EP2252259A2 Parenteral formulations of dopamine agonists |
| 11/24/2010 | EP2252254A2 Compositions and devices |
| 11/24/2010 | EP2252169A2 Beverage comprising arginine |
| 11/24/2010 | EP2252158A1 Method of producing a bran product |
| 11/24/2010 | EP2252151A1 Quinolizidinone m1 receptor positive allosteric modulators |
| 11/24/2010 | EP2252150A1 Selective opioid compounds |
| 11/24/2010 | EP2252149A2 A method for the preparation of fentanyl |
| 11/24/2010 | EP2252148A1 Methods for treating bowel diseases |
| 11/24/2010 | EP2152711B1 2 -heteroaryl- pyrrolo [3, 4-c]pyrrole derivatives and their use as scd inhibitors |
| 11/24/2010 | EP2091531B1 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting mpt |
| 11/24/2010 | EP2089031B1 Reduction of overweight or obesity |
| 11/24/2010 | EP2089015B1 Methods for treating disruptive behavior disorders |
| 11/24/2010 | EP2063868B1 Pharmaceutical compositions containing rosuvastatin calcium |
| 11/24/2010 | EP2040700B1 N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration |
| 11/24/2010 | EP2038288B1 Novel 4-amino-3-(-azolyl-phenoxymethyl)-thienoý3,2¨pyridine-7-carboxylic acid derivatives |
| 11/24/2010 | EP2034999B1 Dha esters and use thereof in the treatment and the prevention of cardiovascular diseases |
| 11/24/2010 | EP2019823B1 Benzamide glucokinase activators |
| 11/24/2010 | EP1987023B1 Hydrate forms of amg706 |